Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Monica Mita"'
Autor:
Sapna Patel, Alain Mita, Kyriakos P Papadopoulos, Justine Cohen, Alexander Shoushtari, Jordi Rodon, Marlana Orloff, Marya Chaney, Carolyn Muller, Jessica Lin, Tina Garyantes, Monica Mita, Christopher Natale, Jeffrey Ishizuka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/eea4b5f77786436a94e0b9b2b34ee5b4
Autor:
Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta, Razelle Kurzrock
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Abstract Background The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies. Methods M2698 was administer
Externí odkaz:
https://doaj.org/article/a4b6ff9c3cf54aeebe10a0ef9f20a8b8
Autor:
Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N Munster, Luis Paz-Ares, Ellen H Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0221994 (2019)
Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy f
Externí odkaz:
https://doaj.org/article/6826e5d056cc437e95d2b64f908d0efe
Autor:
Daniel Von Hoff, Christopher Stogard, Susan O'Brien, Januario Castro, Nicole Lamanna, Udai Banerji, Monica Mita, Chris Takimoto, Muhammad Wasif Saif
PDF file 76K, Demographic characteristics of Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8925c92e6f1a56593a21350174eb44c
https://doi.org/10.1158/1078-0432.22449017.v1
https://doi.org/10.1158/1078-0432.22449017.v1
Autor:
H. Miles Prince, Ricky W. Johnstone, Kenneth Culver, Margaret Dugan, Dale Butterfoss, Peter Atadja, Gail Ryan, Howard Burris, Joachim Beck, Monica Mita, Roxanne Williams-Truax, Chris McCormack, Daniel J. George, Gordon K. Smyth, Yan Pan, Leigh Ellis
Supplementary Tables 1-3 from Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463e094057a17a83cc864d0e83c33bc3
https://doi.org/10.1158/1078-0432.22439467.v1
https://doi.org/10.1158/1078-0432.22439467.v1
Autor:
Chris H. Takimoto, Sridhar Mani, Dale E. Shuster, Mendel Jansen, Fang Fang, Christopher Desjardins, Nancy Wong, Quincy S. Chu, Eric K. Rowinsky, Monica Mita, Alain C. Mita, Sanjay Goel
Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a351f344895b818e22174cb35314bb7
https://doi.org/10.1158/1078-0432.22440229.v1
https://doi.org/10.1158/1078-0432.22440229.v1
Autor:
Daniel Von Hoff, Christopher Stogard, Susan O'Brien, Januario Castro, Nicole Lamanna, Udai Banerji, Monica Mita, Chris Takimoto, Muhammad Wasif Saif
Supplementary Figure Legends - PDF file 90K, supplementary figures legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9877e5427c1361756a92232e84c61ac4
https://doi.org/10.1158/1078-0432.22449023.v1
https://doi.org/10.1158/1078-0432.22449023.v1
Autor:
Monica Mita, Bruce A. Silver, Cheryl Eaton, Lisa Iacono, Jochem Gokemeijer, Eric Furfine, Kamalesh Sankhala, Alain C. Mita, Elena G. Chiorean, Amita Patnaik, Kyri Papadopoulos, Christopher J. Sweeney, Anthony W. Tolcher
Purpose: To determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), a VEGFR-2 inhibitor and the first human fibronectin domain–based targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3210a253c35d84e41216bfa935a3c6
https://doi.org/10.1158/1078-0432.c.6519701.v1
https://doi.org/10.1158/1078-0432.c.6519701.v1
Autor:
Daniel Von Hoff, Christopher Stogard, Susan O'Brien, Januario Castro, Nicole Lamanna, Udai Banerji, Monica Mita, Chris Takimoto, Muhammad Wasif Saif
Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin–based HSP90 inhibitor that showed activity in preclinical models at low nanomolar concentrations. We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bceba4cf04ce0763a8b37a294c5f220
https://doi.org/10.1158/1078-0432.c.6521537.v1
https://doi.org/10.1158/1078-0432.c.6521537.v1
Autor:
Daniel Von Hoff, Christopher Stogard, Susan O'Brien, Januario Castro, Nicole Lamanna, Udai Banerji, Monica Mita, Chris Takimoto, Muhammad Wasif Saif
CCR Translation for This Article from A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bc160097bc0a4906b93700cd179387d
https://doi.org/10.1158/1078-0432.22449026.v1
https://doi.org/10.1158/1078-0432.22449026.v1